Streetbeat News

Stock Prices

MINT

Investors are increasingly turning to cash, making money market ETFs attractive investment options. This trend suggests a growing preference for liquidity and safety in uncertain market conditions.

Portfolio Pulse from

December 09, 2024 | 7:15 pm

ASPI

Johnson Fistel, LLP has initiated a class action lawsuit on behalf of ASP Isotopes Inc. investors who acquired securities between October 30, 2024, and November 26, 2024. The lawsuit aims to recover investor losses, and the deadline to apply as lead plaintiff is February 3, 2025.

Portfolio Pulse from

December 09, 2024 | 7:15 pm

BX

The CNBC 'Halftime Report' Investment Committee discussed Blackstone and other financial names, potentially impacting investor sentiment towards these entities.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

GSK

GSK's experimental cancer drug Blenrep, when combined with other treatments, has shown a 42% reduction in the risk of death for multiple myeloma patients at or after first relapse compared to existing treatments.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

BBAI

BigBear.ai's stock is experiencing a significant surge, with a 13.6% increase in share price as of 1 p.m. on Monday. This rise indicates strong investor interest or positive developments for the company.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

ADRNY

Ahold Delhaize has seen a 37% increase in value, including FX and dividends, despite 0% EPS growth in 2023 and expected 0% in 2024. The stock returned to its standard valuation, indicating market recognition of its true value.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

CUBI

Shareholders of Customers Bancorp, Inc. (NYSE:CUBI) are encouraged to contact Levi & Korsinsky by January 31, 2025, to discuss potential recovery options under federal securities laws due to investment losses.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

WOLF

Wolfspeed, Inc. is facing a lawsuit for alleged securities law violations. Investors who have incurred losses are encouraged to contact Levi & Korsinsky for potential recovery options.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

AMZN

The article suggests that growth investors should consider buying Amazon (AMZN) due to its strong growth potential and solid growth attributes, which could lead to exceptional returns.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

BCRX

BioCryst Pharmaceuticals is recommended as a 'Buy' due to the success and growth potential of its drug ORLADEYO, despite competition and a one-dimensional revenue stream. Q3 2024 results showed a modest revenue beat but a slight earnings miss, causing a 13% stock drop. ORLADEYO's revenue is expected to reach $1 billion annually by 2029.

Portfolio Pulse from

December 09, 2024 | 7:00 pm